Illumina, Inc. announced on June 23, 2025, that it has entered into a definitive agreement to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets. The transaction is valued at $350 million in cash payable at closing, with up to an additional $75 million in near-term performance-based milestones and royalties.
This acquisition builds on a co-development agreement established between Illumina and SomaLogic in December 2021, aimed at integrating the SomaScan® Proteomics Assay onto Illumina's high-throughput next-generation sequencing (NGS) platforms. Illumina Protein Prep, currently in early access, is set to become broadly available to all customers in the third quarter of 2025.
The combination of SomaLogic's aptamer-based affinity proteomics platform with Illumina's scalable NGS ecosystem, DRAGEN™ software, and Illumina Connected Multiomics is expected to accelerate the technology development roadmap for proteomics. Illumina anticipates this business will become profitable in 2027 on a non-GAAP operating income basis, with non-GAAP operating margins aligning with Illumina's in 2028. The transaction is expected to close in the first half of 2026, subject to regulatory clearance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.